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Smoking is the major cause of cardiovascular disease in the
United States, and stopping smoking after a myocardial
infarction greatly reduces the risk of reinfarction or death
from coronary heart disease (1) . I-lavingag myocardial infarc-
tion propels 209o to 60% of long-term smokers to stop
smoking (2) . But, without intervention, most survivors of
myocardial infarction who quit smoking have a relapse
within 6 months (3) . A hospital stay after a myocardial
infarction provides a truly unique window of opportunity for
smoking intervention-capitalizing on peak motivation to
quit and on a brief period of enforced abstinence . In general,
smoking interventions that are woven into the smoker's
regular medical care settings are the most effective and
cost-effective, and they have proved far more acceptable to
the patient than have the more intensive multisession treat-
ments to which patients with coronary artery disease and
other high risk conditions are often referred (4-6). The
hospital environment offers especially rich opportunities and
resources for smoking cessation treatment : 1) a potent
nonsmoking environment, particularly since the Joint Com-
mittee on Accreditation of Healthcare Organizations
(JCAHO) has ended smoking throughout the hospital for
patients as well as staff members and visitors (7) ; 2) involve-
ment of a multidisciplinary health care team; and 3) treat-
ments that provide help during the most difficult early days
of abstinence and withdrawal and that can be tailored to the
specific needs and concerns of the patient who has survived
a myocardial infarction (8) . However, as Krumholz and his
colleagues (Cohen, Tsevat, Pasternak and Weinstein) (9)
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lament, despite compelling benefits, hospital-based interven-
tions are neither widely disseminated nor commonly reim-
bursed by third-party payers .
The cost estimates presented by Krumholz et al . (9)
should dispel any doubt about whether such programs are
worth their cost. Using purposefully conservative assump-
tions, they estimate that a brief, hospital-based nurse-managed
smoking cessation treatment is 20 to 200 times more cost-
effective for survivors of infarction than other widely
accepted (and commonly reimbursed) medical therapies
ranging from beta-adrenergic antagonist therapy to coronary
artery bypass grafting for left main coronary artery stenosis in
patients with severe angina . They project an intervention
cost of only $230 per year of life saved . Their estimates add
to a small but growing literature on the cost-effectiveness of
smoking cessation treatments (8)-estimating, for instance,
that brief outpatient stop-smoking counseling by pLysicians
costs far less per year of life saved than does office-based
treatment for hypercholesterolemia or mild to moderate
hypertension (10), even when nicotine gum is added (I1) .
Krumholz and colleagues conclude that "organized
smoking cessation programs with telephone follow-up by
trained professionals should be a part of the care for every
smoker who suffers a myocardial infarction ." We strongly
concur. The model they promulgate-developed and evalu-
ated by Taylor and colleagues (12)-can easily be adapted
for use by respiratory care providers, nurses, physician
assistants and other hospital-based allied health care provid-
ers in concert with attending physicians . In fact, there are a
variety of successful models for organizing and staffing
hospital-based interventions (8,13,14), including a counselor-
managed intervention developed and evaluated by Ockene
and colleagues (13) that found similarly impressive 74%
long-term smoking cessation rates among survivors of myo-
cardial infarction. The stop-smoking rates achieved with
such interventions for the postmyocardial infarction patient
are the highest reported for any smoking cessation treatment
(2,8,13,15) . Besides being highly efficacious and cost-
effective, the intervention of Taylor et al . is relatively easy to
implement . The essential elements of this practical and
powerful interveption are these :
1) A hospital policy that prohibited patient smoking not
just in the coronary care unit, but on all wards where
patients were treated, was critical .
2) The timing of the intervention was important-
beginning immediately after transfer from the coronary care
unit and before hospital discharge (or smoking relapse) .
Counseling came at a time of peak patient receptivity and
could focus on helping patients remain smoke-free, rather
than on stopping smoking . New JCAHO regulations now
make this possible in hospitals throughout the U.S
. (7),
3) The intervention paired brief physician advice with
nurse counseling and follow-tip
. Admitting physicians were
asked to give a "firm, unequivocal" stop-smoking message
to all patients while they still were in the coronary care unit .
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(1 -umholz et al
. might have included this component in their
cost model
; however, physician advice was included in both
experimental and usual care conditions .) Antismoking ad-
vice from the physician is likely to have unique credibility
and motivational force-and to lend added authority to
interventions that are delivered primarily by nonphysician
praLtitioners . For instance, one study of patients treated by
experienced nonphysician counselors through a hospital-
ba.ed stop-smoking consultation service found that no pa-
tient who had not received a personal stop-smoking message
from the hospital physician either stopped or significantly
reduced smoking (14) . Conversely, the findings of Taylor
and colleagues make it clear that a physician message alone
will have limited impact unless patients are supplied with
help to stop smoking. This has been well documented for a
variety of medical smoking cessation treatments . A recent
meta-analysis of 39 physician intervention trials (16) found
that the most effective smoking cessation interventions
involved not just multiple treatment modalities and contacts,
but also multiple providers (both physician and nonphysician) .
In 1 the American Medical Association (17) adopted a
formal resolution to "support the concept of inpatient smok-
ing cessation programs which are conducted by appropri-
ately trained health care personnel under the supervision of
a physician ." Such training can occur in a relatively short
period of time . Training for the intervention developed by
Taylor et al . was provided in three 4-h sessions, followed by
supervision based on the review of I case a month for 12
months. Most hospital nurses are interested in such training
(18) . Moreover, intervention guidelines and training materi-
als have been developed not only for nurses (19), but also for
respiratory therapists (20) and physician assistants (21) .
4) Taylor and colleagues wisely combined motivational
and skill-oriented interventions, This is a strategy widely
recommended for medical stop-smoking treatments (22) .
Personalized health risk /benefit education and motivational
counseling is important even for patients with coronary
artery disease (8,13) . The survivor of myocardial infarction
must h that "it's never too late to quit," even after 40 or
50 years of smoking (23). The skill-oriented component of
the intervention of Taylor et al. consisted of giving patients
initial brief counseling along with self-help materials---a
short manual and audiotapes introducing cognitive behav-
ioral strategies for coping with high risk relapse situations-
and following up with brief telephone counseling (for every-
one) and additional face to face counseling for patients who
hay elapsed or had difficulty staying smoke-free .
The follow-up telephone contacts highlighted by Krum-
told eolleka ;1, . represent a relatively low cost and
effMive follow-up counseling strategy (24) . However,
follow-up clinic visits were not as effective . Taylor and
Ilc;4
;ues observed that many of the patients requiring extra
Counseling were those who were not initially motivated to
stop smoking . Among the subgroup of 20 patients on whom
calculations of the time requirement for the intervention
were based, 3 were not highly motivated and required >8 h
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each (including additional clinic visits) . Only one of them
stopped smoking-leading Taylor and colleagues (12) to
conclude that "it may be more appropriate to direct the
intervention to patients more interested in stopping smoking
and to limit intervention to four or five contacts :°y patients
who have not stopped." Dropping these three patients from
the total would have reduced the mean time required for the
intervention from 3 h to 2 h . Following a stepped care
model-in which patients who have a relapse or need extra
help can be triaged and referred either to more intensive
motivational counseling or to cessation counseling-may
prove ultimately the most cost-effective (22) . For patients
who lack the motivation or confidence to quit smoking,
promising new "motivational interviewing" techniques can
increase receptivity to treatment (8,25) and greatly improve
treatment outcome (26). Motivated patients who need extra
help or support to stay smoke free are likely to benefit from
more intensive clinic treatment or one-on-one therapy and,
possibly, from nicotine replacement therapy .
We agree with hhunhoi . tits`/ colleagues that further
examination of nicotine replacement ir. these patients is
needed. Studies of the risks and benefits of transdermal
nicotine are especially important because the transdermal
nicotine offers several advantages over nicotine gum : It is
easier to use, causes fewer side effects and produces higher,
more stable blood nicotine levels and can double the smok-
ing cessation rates of behavioral treatment (27,28) . Limited
available data suggest that, after a careful, individual risk/
benefit appraisal and with careful monitoring and follow-up,
transdermal nicotine may have a legitimate role in the
treatment of highly addicted survivors of myocardial infarc-
tion-using the lower starting doses (i .e., 14 mg) generally
recommended for patients with coronary artery disease
(27,28) . Rennard and colleagues (29) examined the safety
and efficacy of transdermal nicotine in a placebo-controlled
study of 156 smokers with documented stable coronary
artery disease . Using 14-mg patches as the starting dose,
they found that active patch users had short-term smoking
cessation rates almost twice as high as those of placebo
patch users, with no increases in cardiac symptoms or
complications (e .g., angina, palpitation) . More recently,
Benowitz and colleagues (30) compared cigarette smoking,
transdermal nicotine and placebo patches in 12 healthy
smokers to examine the role of nicotine in promoting coag-
ulation and to assess the safety of transdermal nicotine
therapy for smoking cessation. They concluded that trans-
dermal nicotine is likely to be safer than smoking for
smokers with coronary artery disease-in large part because
nicotine levels are considerably lower .
Another consideration for survivors of myocardial infarc-
tion is the risk of smoking while using nicotine gum or
patches. This risk received enormous public attention in
June 1992 with the report of acute myocardial infarction in
five patients with coronary artery disease at one Massachu-
setts hospital who smoked while using the patch (31) . A
recent population-based study of older smokers (a third of
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whom reported a history of heart disease) found that almost
half smoked while using the patch (32) . Smoking while
wearing the patch was inversely related to the number of
patch-related physician and pharmacist contacts-and only
half of these smokers reported any initial physician or
pharmacist advice or materials about proper patch use or
quitting methods! It is reassuring that the Food and Drug
Administration received a total of only 33 reports of adverse
cardiovascular events from December 1991 to July 1992, and
only 47 reports of myow -dial infarction in patients who were
smoking while wearing the patch from December 1991 to
November 1992-a rate of <5 myocardial infarctions/million
transdermal nicotine prescriptions (Daniel Spyker, MD,
personal communication, July 9, 1993) . But to date there are
no data on the risks of concomitant smoking among medi-
cally high risk smokers . Concerns about possible risks make
it imperative that patients with coronary artery disease using
transdermal nicotine be followed tip regularly, be strongly
advised not to smoke and instructed in advance about what
to do in the event that smoking does occur (e.g ., remove
patch for remainder of the day, throw away all remaining
cigarettes, resolve to stay smoke-free, start with a fresh
patch the next day) . Used properly, transdermal nicotine
might even improve treatment cost-effectiveness.
From a practical and cost-effectiveness standpoint, rou-
tine hospital-based treatment for the postmyocardial infarc-
tion patient is clearly an idea whose time has come. We
therefore urge that state and federal regulatory authorities
carefully review the findings presented by Taylor et al . and
Krumholz and colleagues and move to allow hospitals to
include the costs of inpatient quit-smoking counseling in
their rates for reimbursement, and, more generally, that
reimbursement for smoking cessation counseling be included
in the basic preventive health services package now being
considered under health care reform-possibly financed by
the revenues from increased tobacco excise taxes . Finally,
we commend Krumholz et al . for furnishing cost-
effectiveness estimates for this model intervention, thereby
promoting its wider recognition, acceptance and replication .
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